Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 124-135

  Zakrzewicz, Dariusz ^a   Zakrzewicz, Anna ^b   Wilker, Sigrid ^b   Boedeker, Rolf Hasso ^b   Padberg, Winfried ^b   Eickelberg, Oliver ^c   Grau, Veronika ^b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

ADMA; kidney transplantation; l arginine; rat; SDMA

Indexed keywords

6 N,N' DIMETHYLARGININE; N(G),N(G) DIMETHYLARGININE;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DARK AGOUTI RAT; FATALITY; FISCHER 344 RAT; ISOGRAFT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LEWIS RAT; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RAT STRAIN; VASCULAR DISEASE;

ACUTE DISEASE; ANIMALS; ARGININE; BLOTTING, WESTERN; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOENZYME TECHNIQUES; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; NITRATES; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; PROTEIN-ARGININE N-METHYLTRANSFERASES; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSPLANTATION, HOMOLOGOUS;

EID: 78650645669     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq392     Document Type: Article

References (56)

1. Wilcken DE, Sim AS, Wang J et al. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007; 91: 309-317
2. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Ren Physiol 2008; 294: F1-F9
3. Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003; 4: 23-28
4. Boger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med 2005; 10: S1-S2
5. Boger RH, Bode-Boger SM, Tsao PS et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295
6. Closs EI, Basha FZ, Habermeier A et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73
7. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 2005; 35: 71-79
8. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol2003; 23: 567-575
9. Vos IH, Joles JA, Schurink M et al. Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointersti-tial injury in renal allograft rejection. Eur J Pharmacol 2000; 391: 31-38
10. Albrecht EW, van Goor H, Tiebosch AT et al. Nitric oxide production and nitric oxide synthase expression in acute human renal allograft rejection. Transplantation 2000; 70: 1610-1616
11. Akizuki E, Akaike T, Okamoto S et al. Role of nitric oxide and superoxide in acute cardiac allograft rejection in rats. Proc Soc Exp Biol Med 2000; 225: 151-159
12. Joles JA, Vos IH, Grone HJ et al. Inducible nitric oxide synthase in renal transplantation. Kidney Int 2002; 61: 872-875
13. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005; 10: S11-S17
14. Jeremy JY, Rowe D, Emsley AM et al. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43: 580-594
15. Lindholm A, Ohlman S, Albrechtsen D et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: 307-315
16. Tullius SG, Nieminen M, Bechstein WO et al. Contribution of early acute rejection episodes to chronic rejection in a rat kidney retrans-plantation model. Kidney Int 1998; 53: 465-472
17. Tanaka M, Sydow K, Gunawan F et al. Dimethylarginine dimethyl- aminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112: 1549-1556
18. Potena L, Fearon WF, Sydow K et al. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Transplantation 2008; 85: 827-833
19. Joosten SA, Sijpkens YW, van Kooten C et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68: 1-13
20. Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600
21. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176
22. Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
23. Fleck C, Janz A, Schweitzer F et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78: S14-S18
24. Fleck C, Schweitzer F, Karge E et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 2003; 336: 1-12
25. Ravani P, Tripepi G, Malberti F et al. Asymmetrical dimethylarginine predicts progressiontodialysis and deathin patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455
26. Yilmaz MI, Saglam M, Caglar K et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005; 80: 1660-1666
27. Esposito C, Grosjean F, Torreggiani M et al. Increased asymmetric dimethylarginine serum levels are associated with acute rejection in kidney transplant recipients. Transplant Proc 2009; 41: 1570-1573
28. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell 2009; 33: 1-13
29. Paik WK, Kim S. Protein methylase I. Purification and properties of the enzyme. J Biol Chem 1968; 243: 2108-2114
30. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030
31. Leiper JM, Santa Maria J, Chubb A et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214
32. Bulau P, Zakrzewicz D, Kitowska K et al. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol 2007; 292: L18-L24
33. Holler J, Zakrzewicz A, Kaufmann A et al. Neuropeptide Y is expressed by rat mononuclear blood leukocytes and strongly down-regulated during inflammation. J Immunol 2008; 181: 6906-6912
34. Andriambeloson E, Cannet C, Pally C et al. Transplantation-induced functional/morphological changes in rat aorta allografts differ from those in arteries of rat kidney allografts. Am J Transplant 2004; 4: 188-195
35. Fabre J, Lim SH, Morris PJ. Renal transplantation in the rat: details of a technique. Aust N Z J Surg 1971; 41: 69-75
36. Grau V, Herbst B, Steiniger B. Dynamics of monocytes/macrophages and T lymphocytes in acutely rejecting rat renal allografts. Cell Tissue Res 1998; 291: 117-126
37. Hirschburger M, Zakrzewicz A, Kummer Wet al. Nicotine attenuates macrophage infiltration in rat lung allografts. J Heart Lung Transplant 2009; 28: 493-500
38. Bulau P, Zakrzewicz D, Kitowska K et al. Quantitative assessment of arginine methylation in free versus protein-incorporated amino acids in vitro and in vivo using protein hydrolysis and high-performance liquid chromatography. Biotechniques 2006; 40: 305-310
39. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophoto-metric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62-71
40. Chen QQ, Li D, Guo R et al. Decrease in the synthesis and release of calcitonin gene-related peptide in dorsal root ganglia of spontaneously hypertensive rat: role of nitric oxide synthase inhibitors. Eur J Pharmacol 2008; 596: 132-137
41. Carello KA, Whitesall SE, Lloyd MC et al. Asymmetrical dimethy-larginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 2006; 290: H209-H216
42. Boisvert FM, Cote J, Boulanger MC et al. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003; 2: 1319-1330
43. Cardounel AJ, Cui H, Samouilov A et al. Evidence for the patho-physiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-887
44. Zakrzewicz D, Eickelberg O. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med 2009; 9: 5
45. Desai A, Zhao Y, Warren JS. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant 2008; 23: 1513-1520
46. LiVolti G, SorrentiV,Acquaviva Retal. Effect of ischemia-reperfusion on renal expression and activity of N(G)-N(G)-dimethylarginine dimethylaminohydrolases. Anesthesiology 2008; 109: 1054-1062
47. Chen M, Li Y, Yang T et al. ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine 2008; 43: 149-159
48. Schepers E, Glorieux G, Dhondt A et al. Role of symmetric dimethyl-arginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24: 1429-1435
49. Kakimoto Y, Akazawa S. Isolation and identification of N-G, N-G-and N-G, N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyl-lysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-5758
50. Jacobi J, Tsao PS. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Ne-phrol 2008; 28: 224-237
51. Kielstein JT, Salpeter SR, Bode-Boeger SM et al. Symmetric di-methylarginine (SDMA) as endogenous marker of renal function- A meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-2451
52. Wang J, Sim AS, Wang XL et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184: 383-388
53. MacAllister RJ, Parry H, Kimoto M et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540
54. Tojo A, Welch WJ, Bremer V et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601
55. Tang J, Frankel A, Cook RJ et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000; 275: 7723-7730
56. Mowen KA, Schurter BT, Fathman JWet al. Arginine methylation of NIP45 modulates cytokine gene expression in effector T lymphocytes. Mol Cell 2004; 15: 559-571